The global angiotensin II receptor blockers market is expected to grow at a CAGR of 4.5% during the forecast period, to reach USD 3.2 billion by 2030. The growth of this market is driven by the increasing prevalence of chronic kidney diseases and heart failure, which are major indications for ARBs.
The North American region accounted for the largest share in the global ARBs market in 2017, followed by Europe and Asia Pacific respectively. The high prevalence of chronic kidney diseases and heart failure in these regions has led to an increased demand for ARBs as a treatment option for these conditions.
Some Of The Growth Factors Of This Market:
- The increasing prevalence of cardiovascular diseases and the rising incidence of hypertension are the major factors driving the growth of this market.
- The increasing number of patent expiries in developed markets is expected to create opportunities for generic players in developing markets.
- Increasing awareness about lifestyle changes and their impact on health will drive demand for Angiotensin II Receptor Blockers.
- Increasing adoption rates among patients with chronic kidney disease will also fuel the growth of this market.
Industry Growth Insights published a new data on “Angiotensin II Receptor Blockers Market”. The research report is titled “Angiotensin II Receptor Blockers Market research by Types (Azilsartan, Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan), By Applications (Chronic Kidney Diseases, Heart Failure, Kidney Failure in Diabetes), By Players/Companies Merck & Co., AstraZeneca, Novartis, Teva, Bayer, GlaxoSmithKline, Sun Pharmaceutical, Mylan”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Angiotensin II Receptor Blockers Market Research Report
By Type
Azilsartan, Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan
By Application
Chronic Kidney Diseases, Heart Failure, Kidney Failure in Diabetes
By Companies
Merck & Co., AstraZeneca, Novartis, Teva, Bayer, GlaxoSmithKline, Sun Pharmaceutical, Mylan
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
234
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
Global Angiotensin II Receptor Blockers Market Report Segments:
The global Angiotensin II Receptor Blockers market is segmented on the basis of:
Types
Azilsartan, Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Chronic Kidney Diseases, Heart Failure, Kidney Failure in Diabetes
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck & Co.
- AstraZeneca
- Novartis
- Teva
- Bayer
- GlaxoSmithKline
- Sun Pharmaceutical
- Mylan
Highlights of The Angiotensin II Receptor Blockers Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Azilsartan
- Candesartan
- Eprosartan
- Irbesartan
- Losartan
- Olmesartan
- Telmisartan
- Valsartan
- By Application:
- Chronic Kidney Diseases
- Heart Failure
- Kidney Failure in Diabetes
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Angiotensin II Receptor Blockers Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Angiotensin II receptor blockers (ARBs) are medications that block the action of angiotensin II. Angiotensin II is a hormone that helps to regulate blood pressure and fluid balance. ARBs work by blocking the effects of angiotensin II on the body's blood vessels. This can lower blood pressure and help to prevent heart attacks, strokes, and other cardiovascular problems.
Some of the major players in the angiotensin ii receptor blockers market are Merck & Co., AstraZeneca, Novartis, Teva, Bayer, GlaxoSmithKline, Sun Pharmaceutical, Mylan.
The angiotensin ii receptor blockers market is expected to register a CAGR of 4.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Angiotensin II Receptor Blockers Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Angiotensin II Receptor Blockers Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Angiotensin II Receptor Blockers Market - Supply Chain
4.5. Global Angiotensin II Receptor Blockers Market Forecast
4.5.1. Angiotensin II Receptor Blockers Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Angiotensin II Receptor Blockers Market Size (000 Units) and Y-o-Y Growth
4.5.3. Angiotensin II Receptor Blockers Market Absolute $ Opportunity
5. Global Angiotensin II Receptor Blockers Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Angiotensin II Receptor Blockers Market Size and Volume Forecast by Type
5.3.1. Azilsartan
5.3.2. Candesartan
5.3.3. Eprosartan
5.3.4. Irbesartan
5.3.5. Losartan
5.3.6. Olmesartan
5.3.7. Telmisartan
5.3.8. Valsartan
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Angiotensin II Receptor Blockers Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Angiotensin II Receptor Blockers Market Size and Volume Forecast by Application
6.3.1. Chronic Kidney Diseases
6.3.2. Heart Failure
6.3.3. Kidney Failure in Diabetes
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Angiotensin II Receptor Blockers Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Angiotensin II Receptor Blockers Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Angiotensin II Receptor Blockers Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Angiotensin II Receptor Blockers Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Angiotensin II Receptor Blockers Demand Share Forecast, 2019-2026
9. North America Angiotensin II Receptor Blockers Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Angiotensin II Receptor Blockers Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Angiotensin II Receptor Blockers Market Size and Volume Forecast by Application
9.4.1. Chronic Kidney Diseases
9.4.2. Heart Failure
9.4.3. Kidney Failure in Diabetes
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Angiotensin II Receptor Blockers Market Size and Volume Forecast by Type
9.7.1. Azilsartan
9.7.2. Candesartan
9.7.3. Eprosartan
9.7.4. Irbesartan
9.7.5. Losartan
9.7.6. Olmesartan
9.7.7. Telmisartan
9.7.8. Valsartan
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Angiotensin II Receptor Blockers Demand Share Forecast, 2019-2026
10. Latin America Angiotensin II Receptor Blockers Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Angiotensin II Receptor Blockers Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Angiotensin II Receptor Blockers Market Size and Volume Forecast by Application
10.4.1. Chronic Kidney Diseases
10.4.2. Heart Failure
10.4.3. Kidney Failure in Diabetes
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Angiotensin II Receptor Blockers Market Size and Volume Forecast by Type
10.7.1. Azilsartan
10.7.2. Candesartan
10.7.3. Eprosartan
10.7.4. Irbesartan
10.7.5. Losartan
10.7.6. Olmesartan
10.7.7. Telmisartan
10.7.8. Valsartan
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Angiotensin II Receptor Blockers Demand Share Forecast, 2019-2026
11. Europe Angiotensin II Receptor Blockers Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Angiotensin II Receptor Blockers Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Angiotensin II Receptor Blockers Market Size and Volume Forecast by Application
11.4.1. Chronic Kidney Diseases
11.4.2. Heart Failure
11.4.3. Kidney Failure in Diabetes
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Angiotensin II Receptor Blockers Market Size and Volume Forecast by Type
11.7.1. Azilsartan
1.7.2. Candesartan
11.7.3. Eprosartan
11.7.4. Irbesartan
11.7.5. Losartan
11.7.6. Olmesartan
11.7.7. Telmisartan
11.7.8. Valsartan
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Angiotensin II Receptor Blockers Demand Share, 2019-2026
12. Asia Pacific Angiotensin II Receptor Blockers Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Angiotensin II Receptor Blockers Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Angiotensin II Receptor Blockers Market Size and Volume Forecast by Application
12.4.1. Chronic Kidney Diseases
12.4.2. Heart Failure
12.4.3. Kidney Failure in Diabetes
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Angiotensin II Receptor Blockers Market Size and Volume Forecast by Type
12.7.1. Azilsartan
12.7.2. Candesartan
12.7.3. Eprosartan
12.7.4. Irbesartan
12.7.5. Losartan
12.7.6. Olmesartan
12.7.7. Telmisartan
12.7.8. Valsartan
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Angiotensin II Receptor Blockers Demand Share, 2019-2026
13. Middle East & Africa Angiotensin II Receptor Blockers Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Angiotensin II Receptor Blockers Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Angiotensin II Receptor Blockers Market Size and Volume Forecast by Application
13.4.1. Chronic Kidney Diseases
13.4.2. Heart Failure
13.4.3. Kidney Failure in Diabetes
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Angiotensin II Receptor Blockers Market Size and Volume Forecast by Type
13.7.1. Azilsartan
13.7.2. Candesartan
13.7.3. Eprosartan
13.7.4. Irbesartan
13.7.5. Losartan
13.7.6. Olmesartan
13.7.7. Telmisartan
13.7.8. Valsartan
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Angiotensin II Receptor Blockers Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Angiotensin II Receptor Blockers Market: Market Share Analysis
14.2. Angiotensin II Receptor Blockers Distributors and Customers
14.3. Angiotensin II Receptor Blockers Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Merck & Co.
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. AstraZeneca
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Novartis
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Teva
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Bayer
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. GlaxoSmithKline
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Sun Pharmaceutical
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Mylan
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
